A recent study from the Humanitas Clinical and Research Center, Rozzano (Milan) 20089, Italy shows that “PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer.” This study was published in the 12 February 2015 issue of the Journal “Cell” [I.F:33] by Drs. Alberto Mantovani , Eduardo Bonavita and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Inflammation-mediated cancers: Tumor suppressor ARF increases the expression of oncogenic suppressor PTX3 and inhibits complement-dependent inflammation via down regulation of its target gene. Thus, pharmacological formulations encompassing may be used to treat patients suffering from inflammation-mediated tumorigenesis.
Idea Proposed/Formulated by: Dr L Boominathan Meeting pods are essentially a little room within a room. They are primarily used for meetings, hence the name, but can be used for all kinds of purposes. These meeting pods come in all shapes and sizes to meet different needs. Pods can be open like the office itself or closed off for privacy and confidentiality. Closed pods are more beneficial because of their natural soundproofing. Open pods still have some basic level of soundproofing, so people can still hold private conversations. soundproof pod Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for Inflammation-mediated cancers: Tumor suppressor ARF increases the expression of oncogenic suppressor PTX3 and inhibits complement-dependent inflammation via down regulation of its target gene, 14/March/2015, 9.03 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Undisclosed information: How ARF increases the expression of PTX3